Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held by Relmada Therapeutics, Inc. on February 27, 2019. The filing details the voting outcomes for director elections, auditor ratification, and amendments to equity plans and the Articles of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Of the 29,764,210 shares eligible to vote, 18,314,149 shares (approximately 61.5%) were present in person or by proxy. All four proposals submitted were approved:
- Proposal 1 (Director Election): Maged Shenouda was elected as a Class I director for a 36-month term. Votes: 15,783,531 For, 126,592 Against, 28,948 Abstain.
- Proposal 2 (Auditor Ratification): Marcum LLP was ratified as the Independent Registered Public Accounting Firm for the fiscal year ending June 30, 2019. Votes: 18,192,200 For, 74,631 Against, 47,318 Abstained.
- Proposal 3 (Equity Plan Amendment): An amendment to the 2014 Stock Option and Equity Incentive Plan to increase authorized shares by 4.0 million was approved. Votes: 13,644,050 For, 2,281,878 Against, 13,143 Abstained.
- Proposal 4 (Authorized Shares Increase): An amendment to the Articles of Incorporation to increase authorized common stock by 100 million shares was approved. Votes: 17,393,096 For, 798,929 Against, 122,124 Abstained.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the impact of the 100 million share increase in authorized common stock on potential future dilution.
- Confirm the details of the 4.0 million share increase to the Stock Option and Equity Incentive Plan.
- Note the significant number of broker non-votes (2,375,078) recorded for the director election and equity plan amendment.
- Review the full 2018 Annual Report (10-K) for the financial data referenced in the auditor ratification.